Ossiform

Ossiform is a MedTech company focused on developing and manufacturing 3D-printed, bio-integrative, patient-matched ceramic bone implants. These implants are designed to enhance the treatment of bone defects by promoting natural bone regeneration and improving patient recovery. Ossiform utilizes a novel bio-ink technology called P3D Bone, which allows for the creation of fully resorbable bone graft substitutes made from β-tricalcium phosphate, a material recognized for its compatibility with the body. The company’s workflow incorporates patient-specific data from medical imaging to create custom implants that fit anatomical defects precisely. This patient-centric approach is supported by software solutions that facilitate collaboration between Ossiform and surgeons, ensuring that the implants meet clinical requirements. Founded in 2015, Ossiform has raised EUR 10 million by 2022 to advance its technology and expand production capabilities, with plans for FDA approval in the United States and subsequent entry into the European market. The company operates from Denmark and the UK, providing solutions primarily for orthopedic and spinal fusion surgeries.

• Employees 10
• Founded 2017
• Total Funding $6700000